Last reviewed · How we verify
NCT05660759
Comparison of N-butyl-cyanoacrylate and Micro Parti-cles Effect in Inducing Liver Hypertrophy After PVE
trial testing Portal vein embolization in Portal Vein Embolization, Liver, Hypertrophy in 265 participants. Completed in 13 December 2022.
13 December 2022
Quick facts
| Lead sponsor | Linkoeping University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 265 |
| Start date | 13 December 2022 |
| Primary completion | 13 December 2022 |
| Estimated completion | 13 December 2022 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Portal vein embolization
Conditions studied
- Portal Vein Embolization, Liver, Hypertrophy — all drugs for Portal Vein Embolization, Liver, Hypertrophy →
Sponsor
Linkoeping University
Who can join
18 and older, any sex, with Portal Vein Embolization, Liver, Hypertrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to compare hypertrophy of the FLR after PVE with microparticles to hypertrophy after PVE with cyanoacrylate in a material large enough to answer the study question. In addition, other factors that may influence the degree of hypertrophy will be evaluated in a multivariable analysis. The hypothesis is: PVE with cyanoacrylate is superior to PVE with microparticles in terms of FLR hy-pertrophy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05660759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Portal vein embolization
Trials testing the same drug.
- NCT05339984 — Hepatic and Systemic Hemodynamic Modeling During Liver Surgery · NA · recruiting
- NCT02618447 — 4D Phase Contrast MR: Hypertrophy in Liver Cancer · NA · terminated
- NCT04182386 — Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization · unknown
Other Linkoeping University trials
Trials by the same sponsor.
- NCT07494422 — A Path to Prevention of Elder Abuse in Long-term Care. Prevalence Study Among Staff in Long-term Care. · not yet recruiting
- NCT07485439 — Self-inspired & Tailored Autism Movement With Phystic App · NA · enrolling by invitation
- NCT07391540 — ICBT for Psychological Symptoms Related to Economy · NA · recruiting
- NCT07181213 — Genetic Predisposition to High Blood Pressure · NA · enrolling by invitation
- NCT07312136 — MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05660759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Linkoeping University
- Last refreshed: 21 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05660759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing